



INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY of WASHINGTON

Meeting Minutes

Date: Friday, March 20, 2020

Time: 10:00 AM – 11:00 AM

Location: Health Sciences Building, Room T269; Remote via Zoom

Members Present:

1. Thea Brabb, Comparative Medicine (*Animal Containment Expert*)
2. Lesley Colby, Comparative Medicine (*Animal Containment Expert*)
3. Richard Grant, Washington National Primate Research Center
4. Garry Hamilton (*Community Member*)
5. Kevin Hybiske, Allergy and Infectious Diseases
6. David Koelle, Allergy and Infectious Diseases
7. Stephen Libby, Laboratory Medicine (*IBC Chair*)
8. Susan Parazzoli (*Community Member*)
9. Jason Smith, Microbiology (*IBC Vice Chair*)
10. Eric Stefansson, Environmental Health & Safety (*Biosafety Officer, Animal Containment Expert*)
11. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

Commonly Used Abbreviations

IBC: Institutional Biosafety Committee

BSO: Biological Safety Officer

BUA: Biological Use Authorization

BSL: biosafety level

PI: Principal Investigator

IACUC: Institutional Animal Care and Use Committee

NIH: National Institutes of Health

DURC: Dual Use Research of Concern

SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:00 a.m. A quorum was present.
2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.
3. **SUBCOMMITTEE REPORTS:**
 - a. Coler, Rhea, new, *Development of Vaccines and Therapeutics for Mycobacterium Tuberculosis in the Preclinical Mouse Model*
 - Four members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
 - The goal of this project is to find an effective vaccine that can be used along with a therapeutic regime against human tuberculosis (TB) disease. This will involve testing novel vaccines and treatment and delivery systems as well as understanding the immunological basis of a protective anti-tuberculosis response.
 - Mycobacterium tuberculosis infected mice will be moved to a SLU3.1 ABSL3 room. UW Comparative Medicine (DCM) staff will be responsible for the transfer and subsequent rehousing.
 - No member of the Coler lab will be allowed to handle infectious agents or be in the BSL3 area until all training is complete. DCM will be responsible for the mice until then.
 - At the request of the committee, information was provided by the PI to state that the H37Rv-INH resistant strain remains rifampicin sensitive.
 - The draft BUA letter was shown.
 - A member made a motion to approve the draft BUA letter for Dr. Coler. Another member seconded the motion.
 - The Committee voted unanimously to approve the draft BUA for Dr. Coler.
4. **ISSUES FROM THE FLOOR & PUBLIC COMMENTS:** There were no issues from the floor, and no public comments.
5. **MEETING ADJOURNED AT APPROXIMATELY 10:40 A.M.**